ALS Association Launches Campaign to Combat Insurance Denials

The initiative centers on the Undeniable Kit, a free resource designed to help patients challenge denials for treatments, power wheelchairs, and in-home care. The organization acted after its internal review found that nearly all of 19 major commercial insurers impose clinical hurdles for the gene-targeted drug Qalsody that were never required by the FDA. About one-third of these insurers classify the FDA-approved treatment as investigational, effectively blocking access for patients who have only a two-to-five-year life expectancy following diagnosis.

For families like the Gonzalez household in Utah, these administrative barriers translate into lost time that cannot be recovered. Although the association successfully overturned a denial for Kayla Gonzalez, the process underscored the exhaustion families face when navigating complex insurance systems. The campaign aims to shift the burden away from patients by advocating for a policy where physician-prescribed treatments receive automatic coverage once approved by federal regulators.